A $63m VC Round Takes E-Scape Into Clinic With Alzheimer's, Parkinson's Drugs
E-Scape's Series A cash will fund the development of small molecules targeting genetic drivers of neurodegenerative diseases, such as ApoE4 in Alzheimer's disease. The venture capital financing with big pharma backing will be used to take two programs into the clinic.
You may also be interested in...
Accera Posts Phase III Alzheimer's Failure, But Moves Ahead With New Formulation
Accera blamed the study's failure on a revised formulation for AC-1204, but the company plans to begin a second Phase III trial with an improved formulation of the drug in the second or third quarter of 2017.
After Solanezumab, What’s Next? Alzheimer’s Options Take The Stage At CTAD
Lilly will make its first presentation of solanezumab data from the recently failed Phase III EXPEDITION3 study during the Clinical Trials in Alzheimer’s Disease meeting where researchers will discuss amyloid beta and other hypotheses in Alzheimer’s disease Dec. 8-10 in San Diego.
Alzheon's Reclaimed Alzheimer's Drug Has Potential To Win Big – If History Doesn't Repeat
New data for Alzheon's Alzheimer's disease drug, tramiprosate, from two Phase III trials that failed to show efficacy in 2007 may shed light on how the company can better design new trials for follow-on product ALZ-801, for which it will initiate pivotal Phase III studies next year.